Roland Wohlgemuth studied chemistry and biology at the University of Basel in Switzerland and obtained his Ph.D. with Prof. Joachim Seelig in 1979 at the Biocenter of the University of Basel. He did postdoctoral work at the Biocenter of the University of Basel and at the Lawrence Berkeley Laboratory and UC Berkeley with a Swiss National Science Foundation Award in 1980 and a US Department of Energy employment with Prof. Melvin Calvin from 1981-1983. From 1983 on Roland Wohlgemuth has lead and built up the bioanalytical and biochemistry/biotechnology laboratories at Fluka in Switzerland. In 1989 Fluka became part of the Sigma-Aldrich Corporation, which in 2015 was itself acquired by Merck KGaA. Research interests are at the molecular and engineering interface of medicine-biology-chemistry, in the areas of biocatalysis, glycobiology, metabolomics, protein analysis, bioanalytical technologies, molecular medicine, technical biochemistry, industrial biotechnology and bioeconomy. In 2017 Roland Wohlgemuth moved from industry to academia, working as Professor at the Institute of Molecular and Industrial Biotechnology of Lodz University of Technology. Roland Wohlgemuth is cofounder of the Swiss Industrial Biocatalysis Consortium, Chairman of the European Society of Applied Biocatalysis (ESAB) and President of the Swiss Coordination Committee Biotechnology (SKB).